Search
Testosterone enanthate
go.drugbank.com/drugs/DB13944ApprovedInvestigationalThis slow release is achieved by the presence of the enanthate ester functional group attached to the testosterone molecule.
Dotatate gallium Ga-68
go.drugbank.com/drugs/DB13925ApprovedInvestigationalWithdrawn[A31358] Dotatate gallium 68 was developed by Advanced Accelerator Applications USA, Inc. and FDA approved in June 1, 2016.
Lobeline
go.drugbank.com/drugs/DB05137InvestigationalAn alkaloid that has actions similar to nicotine on nicotinic cholinergic receptors but is less potent.
Tamsulosin
go.drugbank.com/drugs/DB00706ApprovedInvestigational[A178351] Tamsulosin was first approved by the FDA on April 15, 1997.[L6238]
Phenyl salicylate
go.drugbank.com/drugs/DB11071ApprovedIt is an active ingredient in some pharmaceutical products as a mild analgesic for pain relief by releasing salicylate (found in [DB00945] ). … It is synthesized by heating salicylic acid with phenol [L2468], [MSDS]. Phenyl salicylate is used as a food additive in the USA [L2479].
Lusutrombopag
go.drugbank.com/drugs/DB13125ApprovedInvestigationalLusutrombopag is an orally bioavailable thrombopoietin receptor (TPOR) agonist developed by Shionogi & Company (Osaka, Japan). … Lusutrombopag was approved by the FDA on July 31st, 2018 for the same therapeutic indication under the market name Mulpleta.
Edetic acid
go.drugbank.com/drugs/DB00974ApprovedInvestigationalVet approvedA chelating agent (chelating agents) that sequesters a variety of polyvalent cations. It is used in pharmaceutical manufacturing and as a food additive.
Bordetella pertussis fimbriae 2/3 antigen
go.drugbank.com/drugs/DB10790ApprovedInvestigationalBordetella pertussis fimbriae 2/3 antigen is a vaccine for the prophylaxis of the disease caused by Bordetella pertussis which is a a Gram-negative coccobacillus that expresses two serologically distinct
Alglucerase
go.drugbank.com/drugs/DB00088ApprovedWithdrawnAlglucerase is prepared by modification of the oligosaccharide chains of human Beta-glucocerebrosidase. … Alglucerase was first approved by the FDA in 1991;[A254816] however, it was later discontinued from the market.
Human papillomavirus type 33 L1 capsid protein antigen
go.drugbank.com/drugs/DB10311ApprovedInvestigationalIt is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) type 33. … The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Type 33 which are produced by separate fermentations in recombinant *Saccharomyces cerevisiae